查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2055160

生技藥品契約製造市場：依服務類型、生技藥品類型、生產系統、規模、公司規模、治療領域及地區分類

Biologics Contract Manufacturing Market, By Service Type, By Biologic Type, By Production System, By Scale, By Company Size, By Therapeutic Area, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到2026年，生技藥品契約製造市場規模將達到397.2億美元，到2033年將達到804億美元。預計從2026年到2033年，該市場將以10.6%的複合年成長率成長。

分析範圍 分析詳情
基準年 2025 市場規模（2026 年） 397.2億美元
效能數據 2020-2024 預測期 2026-2033
預測期（2026-2033 年）複合年成長率 10.60% 預計金額（2033 年） 804億美元

全球生技藥品契約製造市場是醫藥外包產業的重要組成部分，涵蓋單株抗體、疫苗、細胞和基因療法以及重組蛋白等複雜生物製藥的專業生產服務。對於尋求最佳化營運成本、加快救命治療方法上市速度，同時又能利用外部專業知識、先進生產能力和合規性的製藥和生物技術公司而言，該市場正逐漸成為一種策略解決方案。

該領域的契約製造組織 (CMO) 提供從製程開發和規模化生產到商業化生產、品管和法規遵循的全面服務。生物製藥日益複雜，加之嚴格的監管要求以及建設先進生產設施所需的大量資本投入，正推動著從老牌製藥巨頭到新興生物技術公司等眾多企業採用外包策略。該市場涵蓋多種治療領域，包括腫瘤、自體免疫疾病、感染疾病和罕見疾病，其生產服務範圍從早期臨床試驗樣本到大規模商業化生產。因此，它已成為現代生物製藥價值鏈中不可或缺的組成部分。

市場動態

全球生技藥品契約製造市場受多種強勁因素驅動。其中最主要的促進因素是生物製藥研發管線的指數級成長，目前全球有超過7000種生物製藥處於不同的臨床開發階段，催生了對專業化生產能力的空前需求。生物製藥，尤其是CAR-T細胞療法和基因療法等先進治療方法，其複雜性日益增加，需要精湛的生產技術，許多公司更傾向於外包而非內部研發。不斷攀升的研發成本（有時每種核准藥物的研發成本超過26億美元），加上對專業設施、設備和法規專業知識的需求，使得契約製造成為一種極具吸引力的成本最佳化策略。

此外，隨著慢性病盛行率的上升和全球人口老化的加劇，對生物製藥的需求持續成長。然而，市場也存在著許多限制因素。這些因素包括：嚴格的監管要求可能導致合規性挑戰和延誤；複雜的品管可能影響產品的均一性和安全性；以及在新冠疫情期間暴露出的供應鏈脆弱性。智慧財產權問題和技術轉移方面的挑戰也阻礙了外包決策。儘管有這些挑戰，但巨大的機會也正在湧現，例如：生物相似藥市場的擴張（該市場需要經濟高效的生產解決方案）；個人化醫療和細胞療法的需求不斷成長；新興市場生物製藥活動的拓展；以及連續生產和一次性使用技術的進步，這些進步提高了生物製藥生產的效率和柔軟性。

本報告的主要特點

  • 本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
  • 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
  • 本節根據公司概況、產品系列、主要亮點、財務績效和策略等各種參數，對全球生技藥品契約製造市場的主要公司進行介紹。
  • 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
  • 《全球生技藥品契約製造市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
  • 相關人員可以透過分析全球生技藥品契約製造市場中使用的各種策略矩陣來促進決策。

目錄

第1章：分析目標與假設

  • 分析目的
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要

第3章：市場動態、監管與趨勢分析

  • 市場動態
  • 促進因素
  • 抑制因子
  • 機會
  • 影響分析
  • 主要進展
  • 監管趨勢
  • 產品上市及核准
  • PEST分析
  • 波特的分析
  • 併購情景
  • 產業趨勢

第4章：全球生技藥品契約製造市場：依服務類型分類（2021-2033 年）

  • 原料藥（API）生產
  • 藥品/製劑，無菌填充（FDF）
  • 分析和品管服務
  • 製程開發、規模化/技術轉移
  • 包裝、貼標及相關服務

第5章：全球生技藥品契約製造市場：依生技藥品類型分類（2021-2033 年）

  • 單株抗體（mAbs）
  • 重組蛋白質和酶
  • 疫苗
  • 細胞和基因治療
  • 抗體藥物複合體（ADC）
  • 其他（生長因子、細胞激素、融合蛋白）

第6章：全球生技藥品契約製造市場：依生產系統分類（2021-2033 年）

  • 哺乳動物系統（CHO、NS0、HEK）
  • 微生物系統（大腸桿菌、酵母菌）
  • 替代/新興系統（昆蟲細胞、植物、無細胞系統）

第7章 全球生技藥品契約製造市場：依規模分類（2021-2033 年）

  • 臨床前和臨床規模生產
  • 以市場規模為基礎進行生產

第8章：全球生技藥品契約製造市場：依公司規模分類（2021-2033 年）

  • 中小型契約製造公司
  • 大型契約製造公司（CMO/CDMO）

第9章 全球生技藥品契約製造市場：依治療領域分類（2021-2033 年）

  • 腫瘤/血液系統疾病
  • 免疫學/自體免疫疾病
  • 感染疾病與疫苗
  • 心血管/腎臟疾病
  • 神經系統疾病/中樞神經系統疾病
  • 代謝和內分泌疾病（例如，糖尿病、肥胖、甲狀腺疾病）
  • 呼吸系統疾病
  • 其他（皮膚病學、罕見疾病和孤兒病）

第10章：全球生技藥品契約製造市場：按地區分類（2021-2033 年）

  • 北美洲
    • 美國
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他拉丁美洲國家
  • 歐洲
    • 德國
    • 英國
    • 西班牙
    • 法國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • ASEAN
    • 其他亞太國家
  • 中東
    • 海灣合作理事會國家
    • 以色列
    • 其他中東國家
  • 非洲
    • 南非
    • 北非
    • 中非

第11章 競爭格局

  • Lonza
  • Thermo Fisher Scientific
  • Catalent
  • Samsung Biologics
  • WuXi Biologics
  • Boehringer Ingelheim BioXcellence
  • Fujifilm Diosynth Biotechnologies
  • AGC Biologics
  • Recipharm
  • Siegfried
  • Rentschler Biopharma
  • Abzena
  • Charles River Laboratories
  • IDT Biologika
  • Avid Bioservices

第12章 分析師建議

  • 機會
  • 分析師意見
  • Coherent Opportunity Map (COM)

第13章 參考文獻與分析方法

  • 參考
  • 分析方法
  • 關於 Coherent Market Insights
簡介目錄
Product Code: CMI8662

Biologics Contract Manufacturing Market is estimated to be valued at USD 39.72 Bn in 2026 and is expected to reach USD 80.40 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.6% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 39.72 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 10.60% 2033 Value Projection: USD 80.40 Bn

The global biologics contract manufacturing market represents a critical segment of the pharmaceutical outsourcing industry, encompassing specialized manufacturing services for complex biological products including monoclonal antibodies, vaccines, cell and gene therapies, and recombinant proteins. This market has emerged as a strategic solution for pharmaceutical and biotechnology companies seeking to leverage external expertise, advanced manufacturing capabilities, and regulatory compliance while optimizing operational costs and accelerating time-to-market for life-saving therapies.

Contract manufacturing organizations (CMOs) in this space provide comprehensive services ranging from process development and scale-up to commercial manufacturing, quality control, and regulatory support. The increasing complexity of biological products, coupled with stringent regulatory requirements and substantial capital investments required for state-of-the-art manufacturing facilities, has driven the adoption of outsourcing strategies among both established pharmaceutical giants and emerging biotech companies. The market encompasses various therapeutic areas including oncology, autoimmune diseases, infectious diseases, and rare disorders, with manufacturing services spanning from early-phase clinical trial materials to large-scale commercial production, making it an indispensable component of the modern biopharmaceutical value chain.

Market Dynamics

The global biologics contract manufacturing market is propelled by several compelling drivers, primarily the exponential growth in biologics pipeline development, with over 7,000 biologics currently in various stages of clinical development worldwide, creating unprecedented demand for specialized manufacturing capacity. The increasing complexity of biological products, particularly advanced therapies like CAR-T cell therapies and gene therapies, requires sophisticated manufacturing expertise that many companies prefer to outsource rather than develop in-house. Rising development costs, which can exceed USD 2.6 billion per approved drug, coupled with the need for specialized facilities, equipment, and regulatory expertise, make contract manufacturing an attractive cost-optimization strategy.

Additionally, the growing prevalence of chronic diseases and aging global population continues to drive demand for biologic treatments. However, the market faces significant restraints including stringent regulatory requirements that can create compliance challenges and delays, quality control complexities that can impact product consistency and safety, and supply chain vulnerabilities exposed during the COVID-19 pandemic. Intellectual property concerns and technology transfer challenges also pose barriers to outsourcing decisions. Despite these challenges, substantial opportunities emerge from the expanding biosimilars market, which requires cost-effective manufacturing solutions, increasing demand for personalized medicine and cell-based therapies, growing biopharmaceutical activities in emerging markets, and technological advancements in continuous manufacturing and single-use technologies that enhance efficiency and flexibility in biologics production.

Key Features of the Study

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global biologics contract manufacturing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Lonza, Thermo Fisher Scientific, Catalent, Samsung Biologics, WuXi Biologics, Boehringer Ingelheim BioXcellence, Fujifilm Diosynth Biotechnologies, AGC Biologics, Recipharm, Siegfried, Rentschler Biopharma, Abzena, Charles River Laboratories, IDT Biologika, and Avid Bioservices
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global biologics contract manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biologics contract manufacturing market

Market Segmentation

  • Service Type Insights (Revenue, USD Bn, 2021 - 2033)
  • Drug substance/Active Pharmaceutical Ingredient (API) Manufacturing
  • Drug product/Formulation and Fill-Finish (FDF)
  • Analytical and Quality Control services
  • Process development and scale-up/Technology transfer
  • Packaging, labeling and ancillary services
  • Biologic Type Insights (Revenue, USD Bn, 2021 - 2033)
  • Monoclonal antibodies (mAbs)
  • Recombinant proteins and enzymes
  • Vaccines
  • Cell and gene therapies
  • Antibody-drug conjugates (ADCs)
  • Others (growth factors, cytokines, fusion proteins)
  • Production System Insights (Revenue, USD Bn, 2021 - 2033)
  • Mammalian systems (CHO, NS0, HEK)
  • Microbial systems (E. coli, yeast)
  • Alternative/Emerging systems (insect cells, plant, cell-free)
  • Scale Insights (Revenue, USD Bn, 2021 - 2033)
  • Preclinical/clinical scale manufacturing
  • Commercial scale manufacturing
  • Company Size Insights (Revenue, USD Bn, 2021 - 2033)
  • Small to Mid-sized Contract Manufacturers
  • Large Contract Manufacturing Organizations (CMOs/CDMOs)
  • Therapeutic Area Insights (Revenue, USD Bn, 2021 - 2033)
  • Oncology/Hematology
  • Immunology and Autoimmune Disorders
  • Infectious Diseases and Vaccinology
  • Cardiovascular and Renal Disorders
  • Neurology and Central Nervous System (CNS) Disorders
  • Metabolic and Endocrine Disorders (e.g., diabetes, obesity, thyroid)
  • Respiratory Disorders
  • Others (Dermatology, Rare and Orphan Diseases)
  • Regional Insights (Revenue, USD Bn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
  • Lonza
  • Thermo Fisher Scientific
  • Catalent
  • Samsung Biologics
  • WuXi Biologics
  • Boehringer Ingelheim BioXcellence
  • Fujifilm Diosynth Biotechnologies
  • AGC Biologics
  • Recipharm
  • Siegfried
  • Rentschler Biopharma
  • Abzena
  • Charles River Laboratories
  • IDT Biologika
  • Avid Bioservices

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Biologics Contract Manufacturing Market, By Service Type
    • Global Biologics Contract Manufacturing Market, By Biologic Type
    • Global Biologics Contract Manufacturing Market, By Production System
    • Global Biologics Contract Manufacturing Market, By Scale
    • Global Biologics Contract Manufacturing Market, By Company Size
    • Global Biologics Contract Manufacturing Market, By Therapeutic Area
    • Global Biologics Contract Manufacturing Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Biologics Contract Manufacturing Market, By Service Type, 2021 - 2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Drug substance/Active Pharmaceutical Ingredient (API) Manufacturing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Drug product/Formulation and Fill-Finish (FDF)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Analytical and Quality Control services
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Process development and scale-up/Technology transfer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Packaging, labeling and ancillary services
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Biologics Contract Manufacturing Market, By Biologic Type, 2021 - 2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Monoclonal antibodies (mAbs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Recombinant proteins and enzymes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Cell and gene therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Antibody-drug conjugates (ADCs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Others (growth factors, cytokines, fusion proteins)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Biologics Contract Manufacturing Market, By Production System, 2021 - 2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Mammalian systems (CHO, NS0, HEK)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Microbial systems (E. coli, yeast)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Alternative/Emerging systems (insect cells, plant, cell-free)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Biologics Contract Manufacturing Market, By Scale, 2021 - 2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Preclinical/clinical scale manufacturing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Commercial scale manufacturing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Biologics Contract Manufacturing Market, By Company Size, 2021 - 2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Small to Mid-sized Contract Manufacturers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Large Contract Manufacturing Organizations (CMOs/CDMOs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Biologics Contract Manufacturing Market, By Therapeutic Area, 2021 - 2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Oncology/Hematology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Immunology and Autoimmune Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Infectious Diseases and Vaccinology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Cardiovascular and Renal Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Neurology and Central Nervous System (CNS) Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Metabolic and Endocrine Disorders (e.g., diabetes, obesity, thyroid)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Respiratory Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  • Others (Dermatology, Rare and Orphan Diseases)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

10. Global Biologics Contract Manufacturing Market, By Region, 2021 - 2033, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Service Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Biologic Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Production System, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Scale, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Company Size, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Service Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Biologic Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Production System, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Scale, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Company Size, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Service Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Biologic Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Production System, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Scale, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Company Size, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Service Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Biologic Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Production System, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Scale, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Company Size, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Service Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Biologic Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Production System, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Scale, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Company Size, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Service Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Biologic Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Production System, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Scale, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Company Size, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

11. Competitive Landscape

  • Lonza
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Thermo Fisher Scientific
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Catalent
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Samsung Biologics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • WuXi Biologics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Boehringer Ingelheim BioXcellence
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Fujifilm Diosynth Biotechnologies
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AGC Biologics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Recipharm
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Siegfried
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Rentschler Biopharma
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Abzena
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Charles River Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • IDT Biologika
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Avid Bioservices
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

12. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

13. References and Research Methodology

  • References
  • Research Methodology
  • About Us